NEW YORK (GenomeWeb) – Oxford BioDynamics has made progress toward developing and validating epigenetic signatures for breast cancer and amyotrophic lateral sclerosis.

In recent weeks, the British company has announced the completion of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients. Also this month, the US Patent and Trademark Office granted Oxford BioDynamics a patent covering its EpiSwitch platform, which should support the firm as it looks to build its business in the US.